TET2 antibody (Internal Region)

Catalog No. ABIN569654

The Goat Polyclonal anti-TET2 antibody is suitable to detect TET2 in samples from Human, Mouse and Dog. It has been validated for IHC (p) and EIA.

Quick Overview for TET2 antibody (Internal Region) (ABIN569654)

Target: TET2 (Tet Methylcytosine Dioxygenase 2 (TET2))

Reactivity: Human, Mouse, Dog

Host: Goat

Clonality: Polyclonal

Conjugate: This TET2 antibody is un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA)

Product Details anti-TET2 Antibody

Binding Specificity: Internal Region

Sequence: C-PHPQSNNDQQ REGSF

Specificity: This antibody is expected to recognize both reported isoforms (NP_001120680.1 and NP_060098.3).

Cross-Reactivity (Details): Species reactivity (expected):Mouse and Canine (Dog).
Species reactivity (tested):Human.

Purification: Ammonium Sulphate Precipitation followed by antigen Affinity Chromatography using the immunizing peptide

Immunogen: Peptide with sequence from the internal region of the protein sequence according to NP_001120680.1 and NP_060098.3. Genename: TET2

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.5 mg/mL

Buffer: Tris saline, pH ~7.3 with 0.02 % Sodium Azide and 0.5 % BSA

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid repeated freezing and thawing.

Storage: 4 °C/-20 °C

Storage Comment: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Target Details for TET2

Target: TET2 (Tet Methylcytosine Dioxygenase 2 (TET2))

Alternative Name: TET2

Background: TET2 is frequently mutated in myelodysplastic syndromes, a heterogeneous group of closely related clonal hematopoietic disorders. All are characterized by a hypercellular or hypocellular bone marrow with impaired morphology and maturation, dysplasia of the myeloid, megakaryocytic and/or erythroid lineages, and peripheral blood cytopenias resulting from ineffective blood cell production. Included diseases are: refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB), refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS). Chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative disease. Myelodysplastic syndromes are considered a premalignant condition in a subgroup of patients that often progresses to acute myeloid leukemia (AML). Bone marrow samples from patients display uniformly low levels of hmC in genomic DNA compared to bone marrow samples from healthy controls as well as hypomethylation relative to controls at the majority of differentially methylated CpG sites. It Catalyzes the conversion of methylcytosine (5mC) to 5-hydroxymethylcytosine (hmC). Plays an important role in myelopoiesis. The clear function of 5-hydroxymethylcytosine (hmC) is still unclear but it may influence chromatin structure and recruit specific factors or may constitute an intermediate component in cytosine demethylation. TET2 is Broadly expressed. Highly expressed in hematopoietic cells, highest expression observed in granulocytes. Expression is reduced in granulocytes from peripheral blood of patients affected by myelodysplastic syndromes.Synonyms: KIAA1546, Methylcytosine dioxygenase TET2

Gene ID: 54790

NCBI Accession: NP_001120680

UniProt: Q6N021

Pathways: Warburg Effect